Phase I Study of Ruxolitinib in Previously Treated Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome with Evidence of NF-kB Activation

Therapeutic options for patients with lower-risk myelodysplastic syndrome (MDS) who have failed prior therapies are limited particularly after hypomethylating agent. Several studies have indicated that deregulation of innate immunity signaling is critical in the pathogenesis of MDS. This process inv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Res
Main Authors: Abaza, Yasmin, Hidalgo-Lopez, Juliana E., Verstovsek, Srdan, Jabbour, Elias, Ravandi, Farhad, Borthakur, Gautam, Estrov, Zeev, Alvarado, Yesid, Burger, Jan, Schneider, Heather, Soltysiak, Kelly A., Wei, Yue, Kantarjian, Hagop M., Bueso-Ramos, Carlos E., Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6750211/
https://ncbi.nlm.nih.gov/pubmed/30245189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.09.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados